🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07527884
Recruiting Not applicable

The Effect of Radiotherapy After Separation Surgery for Spinal Metastases

NCT07527884 · tracked via the Priya Life Science China tracker
Sponsor
Wei Xu
Phase
Not applicable
Started
2025-09-01
Last updated
2026-09-16

Condition(s) studied

Spinal MetastasesSpinal TumorRadiotherapySeparation Surgery

Investigational drug(s) / intervention(s)

radiotherapy

radiotherapy: The patients receive radiotherapy after the separation surgery.

Study summary

The aim of this clinical study is to explore the impact of whether radiotherapy is administered after spinal metastasis surgery on the prognosis and survival of patients, to describe the clinical outcomes, and to optimize future clinical decisions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Age over 18 years old, gender not limited; 2. The patient has undergone separation surgery within 3 weeks; 3. The pathological result of the separation surgery site of the patient indicates that the lesion is a metastatic tumor, and the primary lesion is located outside the spine; 4. The expected survival period is ≥ 6 months; 5. The patient has signed the informed consent form. Exclusion Criteria: 1. Patients with poor general condition and those who are intolerant to radiotherapy, chemotherapy, and targeted therapy; 2. Patients whose treatment segments have not received any other surgical treatment or radiotherapy; 3. Patients who participated in other clinical trials of drugs or medical devices within 3 months before enrollment; 4. Other situations judged by the investigator as making the subject unsuitable for enrollment.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Changzheng Hospital Shanghai Shanghai Municipality Recruiting

More Wei Xu trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07527884 on ClinicalTrials.gov ↗ ← All trials in China